Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
NCT07443488
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
HSCT
Ph+ ALL
Interventions
DRUG:
Olverembatinib+INO
Sponsor
Institute of Hematology & Blood Diseases Hospital, China